Fatal Interstitial lung disease after erlotinib for non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 9, 2008, Pages 1050-1053

  Lind, Joline S W ^a   Smit, Egbert F ^a   Grünberg, Katrien ^a   Senan, Suresh ^a   Lagerwaard, Frank J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BICARBONATE; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CARBON DIOXIDE; CEFTRIAXONE; DEXAMETHASONE; ERLOTINIB; ERYTHROMYCIN; FIBRIN; GENTAMICIN; OXYGEN; PREDNISOLONE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ACNE; ADULT; ALKALOSIS; ARTERIAL GAS; ARTICLE; AUTOPSY; BRAIN METASTASIS; BRONCHIECTASIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CARBON DIOXIDE TENSION; CARDIOPULMONARY ARREST; CASE REPORT; CELL HYPERPLASIA; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYANOSIS; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSPNEA; FEMALE; FEVER; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HYALINE MEMBRANE DISEASE; HYPOXIA; INTERSTITIAL LUNG DISEASE; LEUKOCYTE COUNT; LUNG ALVEOLUS CELL TYPE 2; LUNG ANGIOGRAPHY; LUNG DIFFUSION; LUNG EMBOLISM; LUNG FIBROSIS; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MEDIASTINUM LYMPH NODE; OXYGEN SATURATION; OXYGEN TENSION; PH; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; SCLERODERMA; THORAX RADIOGRAPHY; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; FATALITY; LUNG ALVEOLUS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; FATAL OUTCOME; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PULMONARY ALVEOLI; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58149137203     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318183a9f5     Document Type: Article

References (10)

1. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-132.
2. Yoneda KY, Hardin KA, Gandara DR, Shelton DK. Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small cell lung carcinoma. Clin Lung Cancer 2006;8 (Suppl 1):S31-S35.
3. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005;10:461-466.
4. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.
5. Yoneda KY, Shelton DK, Beckett LA, Gandara DR. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer. J Thorac Oncol 2007;2:537-543.
6. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
7. Kishi K, Nakata K, Yoshimura K. Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis. J Thorac Oncol 2006;1:733-734.
8. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556.
9. Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer 2006;52:135-140.
10. Makris D, Scherpereel A, Copin MC, et al. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007;7:150.